The androgen receptor (AR) is the central therapeutic target in advanced prostate cancer. While treatments that directly target AR are effective in prolonging patient survival, aggressive prostate ...

Company to present updated preliminary results from ENLIGHTED Phase 3 Study in LG UTUC -- Additional podium presentation to provide updates ...

A UK study found that using a polygenic risk score to identify men at highest genetic risk of prostate cancer significantly ...

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

Discover a study where findings revealed that total radiographic disappearance of metastases occurred in 15% of patients.

More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the ...

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.

Several biomarker tests have been available for over a decade, with extensive research backing their effectiveness. Yet, many urologists remain unaware of their full potential to streamline practice ...

Formula One team owner Eddie Jordan has died, aged 76, after a year-long battle with prostate and bladder cancer. The Irishman revealed in December he was suffering from bladder and prostate ...

Auron will present data highlighting the activity of AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked ...